0001144204-16-114614.txt : 20160727 0001144204-16-114614.hdr.sgml : 20160727 20160727102310 ACCESSION NUMBER: 0001144204-16-114614 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160727 FILED AS OF DATE: 20160727 DATE AS OF CHANGE: 20160727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRANA BIOTECHNOLOGY LTD CENTRAL INDEX KEY: 0001131343 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-49843 FILM NUMBER: 161785885 BUSINESS ADDRESS: STREET 1: LEVEL 2 STREET 2: 369 ROYAL PARADE CITY: PARKVILLE, VICTORIA STATE: C3 ZIP: 3052 BUSINESS PHONE: 61-3-9349-4906 MAIL ADDRESS: STREET 1: LEVEL 2 STREET 2: 369 ROYAL PARADE CITY: PARKVILLE, VICTORIA STATE: C3 ZIP: 3052 6-K 1 v445151_6k.htm FORM 6-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR

15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2016

 

Prana Biotechnology Limited

(Name of Registrant)

 

Level 2, 369 Royal Parade Parkville  Victoria  3052 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                   Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                      No x 

 

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

 

This Form 6-K is being incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-199783) and Form S-8 (File No. 333-153669).

 

 

 

 

PRANA BIOTECHNOLOGY LIMITED

 

6-K Items

 

1.

Appendix 4C – 4th Quarter

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  PRANA BIOTECHNOLOGY LIMITED
    (Registrant)
     
     
  By: /s/ Geoffrey Kempler  
    Geoffrey Kempler,
    Executive Chairman

  

July 27, 2016

 

 

 

Appendix 4C

Quarterly Report for Entities

Admitted on the Basis of Commitments

 

 

Rule 4.7B

Appendix 4C – 4th Quarter

 

Quarterly report

for entities admitted

on the basis of commitments

 

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

 

 

Name of Entity:
 PRANA BIOTECHNOLOGY LIMITED

 

 

ABN:   Quarter Ended ('Current Quarter')
 37 080 699 065  

30th June 2016

 

Consolidated Statement of Cash Flows

 

 

 

Cash Flows Related to Operating Activities

Current Quarter

$A’000

Year to Date

(9 months)

$A’000

1.1 Receipts from customers - -
1.2

Payments for

  (a) staff costs (683) (2,719)
  (b) advertising and marketing (20) (154)
  (c) research and development (2,234) (9,041)
  (d) leased assets - -
  (e) other working capital (426) (2,146)
1.3 Dividends received - -
1.4 Interest and other items of a similar nature received 24 124
1.5 Interest and other costs of finance paid - -
1.6 Income taxes paid - -
1.7 Other (Grants/Donations) 6,461 6,517
  Net Operating Cash Flows 3,122 (7,420)

 

 

 

+ See chapter 19 for defined terms.

 

17/12/2010 Appendix 4C Page 1

 

 

 

Appendix 4C

Quarterly Report for Entities

Admitted on the Basis of Commitments

 

 

   

Current Quarter

$A’000

Year to Date

(9 months)

$A’000

1.8 Net Operating Cash Flows (carried forward) 3,122 (7,420)
 

 

Cash Flows Related to Investing Activities

   
1.9

Payment for acquisition of:

(a) businesses (item 5)

(b) equity investments

(c) intellectual property

(d) physical non-current assets

(e) other non-current assets

 

-

-

-

-

-

 

-

-

-

(2)

-

1.10

Proceeds from disposal of:

(a) businesses (item 5)

(b) equity investments

(c) intellectual property

(d) physical non-current assets

(e) other non-current assets

 

-

-

-

-

-

 

-

-

-

-

-

1.11 Loans to other entities - -
1.12 Loans repaid by other entities - -
1.13 Other - -
 

 

Net Investing Cash Flows

- (2)
1.14 Total Operating and Investing Cash Flows 3,122 (7,422)
 

 

Cash Flows Related to Financing Activities

   
1.15 Proceeds from issues of shares, options, etc. - -
1.16 Proceeds from sale of forfeited shares - -
1.17 Proceeds from borrowings - -
1.18 Repayment of borrowings - -
1.19 Dividends paid - -
1.20 Other (Capital Raising Costs) - -
  Net Financing Cash Flows - -
 

 

Net Increase / (Decrease) in Cash Held

 

3,122 (7,422)
1.21 Cash at beginning of quarter/year to date 24,813 35,062
1.22 Exchange rate adjustments to item 1.21 659 954
1.23 Cash at End of Quarter             28,594 28,594

 

+ See chapter 19 for defined terms.  
   
Appendix 4C Page 2 17/12/2010

 

 

 

Appendix 4C

Quarterly Report for Entities

Admitted on the Basis of Commitments 

 

 

Payments to Directors of the Entity and Associates of the Directors

 

Payments to Related Entities of the Entity and Associates of the Related Entities

 

 

 

Current Quarter

$A'000

 

1.24

 

Aggregate amount of payments to the parties included in item 1.2

 

 

279

 

1.25

 

Aggregate amount of loans to the parties included in item 1.11

 

 

 

1.26

 

Explanation necessary for an understanding of the transactions

 

 

 

Salaries, directors’ fees and consulting fees at normal commercial rates.

Excludes GST where applicable.

 

 

Non-Cash Financing and Investing Activities

 

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows
 

 

-

 

 

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest
 

 

-

 

 

Financing Facilities Available

 

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

 

   

Amount Available

$A’000

Amount Used

$A’000

3.1

Loan facilities

 

- -
3.2

Credit standby arrangements

 

- -

 

 

+ See chapter 19 for defined terms.  
   
17/12/2010 Appendix 4C Page 3

 

 

 

Appendix 4C

Quarterly Report for Entities

Admitted on the Basis of Commitments

 

 

Reconciliation of Cash

 

Reconciliation of cash at the end of the quarter

(as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

Current Quarter

$A’000

Previous Quarter

$A’000

4.1 Cash on hand and at bank 22,594 24,813
4.2 Deposits at call 6,000 -
4.3 Bank overdraft - -
4.4 Other (provide details) - -
  Total: Cash at End of Quarter (item 1.22) 28,594 24,813

 

Acquisitions and Disposals of Business Entities

 

 

Acquisitions

(Item 1.9(a))

Disposals

(Item 1.10(a))

5.1 Name of entity - -
5.2 Place of incorporation or registration - -
5.3

Consideration for

acquisition or disposal

- -
5.4 Total net assets - -
5.5 Nature of business

-

 

-

 

 

Compliance Statement

 

1This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

 

2This statement does give a true and fair view of the matters disclosed.

 

Sign Here: Date: 27th July 2016  
       
  Company Secretary    
Print Name: Phillip Hains    

 

 

 

 

 

CFO Logo

The CFO Solution

27.07.2016

 

+ See chapter 19 for defined terms.  
   
Appendix 4C Page 4 17/12/2010

 

 

 

Appendix 4C

Quarterly Report for Entities

Admitted on the Basis of Commitments

 

 

Notes

 

1.The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

 

2.The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.

 

3.Accounting Standards. ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

 

 

 

+ See chapter 19 for defined terms.  
   
17/12/2010 Appendix 4C Page 5

 

 

 

GRAPHIC 2 image_004.jpg GRAPHIC begin 644 image_004.jpg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end GRAPHIC 3 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#TV34=)L9K M"SNK9GN;J*)E;>WS%VP<^G3\2<5XYXNL]>U#XI>);6P\176D:-ID<<]Q,;J4 M16Z>6G15.2Q). .IS7M,FO3:=/I-BCV(2>&+(F:0/R</^*=4T MQ/B)\0O#NJ7J6$>LP6Z0WDBDI'+&B,H? )"G.">U &!I^DZUK'B'2M,TSXBW MEQ%JD,DEM<&6=2&0D,CINRI^5B#T./>HH-+\1:EJ&GVVC>/KJ^CNEFDEF:XN M(1;1Q!2SN&YVD-P1UQBG>"X/#WA#XA>'[V?Q+83""&:6_FB9FA1B&1$0[.-0U;2C&7&0&1CG!'(/\J^H/,D_YZ/_ -]&OE[4[C2_ M#GPWG\-6^L6>JZA?ZBMS*]D6:*&)%POS,!EB>PZ"OI^@!MM?ZA"]G;6^G&YM MS:Q,T@<)LR2#UZX !P.?S%<=XD^'OA?6-9N-6U+1[B]O+N]\F1HKF1, ( "% M7CL!^M6GNKB.1XTGE5%.V<=^A^E;GV MZ\_Y^I_^_AI/MUW_ ,_4_P#W\- &';?"GP5=R7$3>&[RW$=KYZS->3%2<=.< H<\Y^F..N.^\Y_4?E7.27ET\;*US,RD$$%R0:[?R(O^>2?]\B@#__V0$! end